- Home
- MIRM vs QBTS Comparison
MIRM vs QBTS Comparison
Compare MIRM & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | QBTS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MIRM | QBTS |
|---|---|---|
| Price | $93.42 | $16.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $119.85 | $32.53 |
| AVG Volume (30 Days) | 456.7K | ★ 14.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $26.22 | $81.05 |
| Revenue Next Year | $22.04 | $93.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.23 | $12.75 |
| 52 Week High | $130.00 | $46.75 |
Technical Indicators
Market Signals| Indicator | MIRM | QBTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 43.68 |
| Support Level | $88.08 | $12.75 |
| Resistance Level | $98.03 | $21.98 |
| Average True Range (ATR) | 3.82 | 0.76 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 1.32 | 22.50 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.